Syndicate content

Multiple Sclerosis (MS) Linked to HHV-6A Variant of Common Herpes Virus Through New Method

Researchers at Karolinska Institutet in Sweden have developed a new method to distinguish between two different types of a common herpes virus (HHV-6) that has been linked to multiple sclerosis (MS). By analyzing antibodies in the blood against the two most divergent proteins of herpesvirus 6A and 6B, the researchers were able to show that MS patients carry the herpesvirus 6A to a greater extent than healthy individuals. The findings, published online on November 26, 2019 in Frontiers in Immunology, point to a role for HHV-6A in the development of MS, which is an autoimmune disease that affects the central nervous system. The open-access article is titled “Increased Serological Response Against Human Herpesvirus 6A Is Associated with Risk for Multiple Sclerosis.” The cause of MS is unclear, but one plausible explanation is that a virus stimulates the immune system to attack the body's own tissue. Human herpesvirus 6 (HHV-6) has previously been associated with MS, but, in those studies, it wasn't possible to distinguish between 6A and 6B. Through virus isolation from ill individuals, researchers have been able to show that HHV-6B can cause mild conditions such as roseola in children, but it has been unclear if HHV-6A is the cause of any disease. According to estimates, as many as 80 percent of all children are infected with the HHV-6 virus before 2 years of age, and many also carry protection in the form of antibodies against this particular virus for the rest of their lives. But because it hasn't been possible to tell the two variants apart post-infection, it has been difficult to say whether HHV-6A or B is a risk factor for MS. In this study, however, the researchers were able to distinguish between the A and B virus by analyzing antibodies in the blood against the two proteins--immediate early protein 1A and 1B (IE1A and IE1B)--that diverge the most between the two viruses.

"This is a big breakthrough for both the MS and herpes virus research," says Anna Fogdell-Hahn (photo), PhD, Associate Professor at the Department of Clinical Neuroscience at Karolinska Institutet, and one of the study's senior authors.

"For one, it supports the theory that HHV-6A could be a contributing factor to the development of MS. On top of that, we are now able, with this new method, to find out how common these two different types of HHV-6 are, something we haven't been able to do previously."

The researchers compared antibody levels in blood samples of some 8,700 MS-patients against those in more than 7,200 healthy people whose gender, date of birth, date of blood sample, and other factors matched those with MS. They concluded that people with MS had a 55 percent higher risk of carrying antibodies against the HHV-6A protein than the control group.

In a sub-group of almost 500 people, whose blood samples were drawn before the onset of the disease, the risk of developing MS in the future was more than doubled if they had a 6A viral infection. The younger the people were when the virus was first discovered in the blood, the higher the risk was of developing MS in the future.

HHV-6B, on the other hand, was not positively associated with MS. Instead, MS-patients had lower levels of antibodies toward IE1B than those without MS.

Antibodies toward Epstein-Barr virus (EBV), another herpes virus that is also associated with MS, were analyzed with the same method and the researchers were able to show that individuals affected with both EBV and HHV-6A had an even greater risk of MS. This indicates that several virus infections could be acting jointly to increase the risk of MS.

"Both HHV-6A and 6B can infect our braincells, but they do it in slightly different ways. Therefore, it is now interesting to go forward and attempt to map out exactly how the viruses could affect the onset of MS," says Associate Professor Fogdell-Hahn.

[Press release] [Frontiers in Immunology article]

https://www.eurekalert.org/pub_releases/2019-11/ki-mlt112519.php
https://www.frontiersin.org/articles/10.3389/fimmu.2019.02715/full
https://media.eurekalert.org/multimedia_prod/pub/web/217915_web.jpg